Elizabeth Johnson

A Phase 2 Clinical Study of HQK-1001 (2,2-dimethylbutyrate, sodium salt), a Fetal Hemoglobin Inducer, in Patients with Sickle Cell Disease

K. Ataga, A. Kutlar, P. Malik, 2011 .

Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial.

Janeen R. Adil, P. Sandercock, Amit Thapa, 2020, Critical care.